News
Why Exact Sciences Shares Are Soaring 11.6% Today
After the company reported better-than-expected top- and bottom-line third-quarter results today, shares of Exact Sciences (NASDAQ: EXAS) are jumping 11.6% at 12:30 p.m. EDT.As many as 20 million....
Novavax Stock Upgraded: 3 Things You Need to Know
Every day, Wall Street analysts upgrade some stocks, downgrade others, and "initiate coverage" on a few more. But do these analysts even know what they're talking about? Today, we're taking one....
Why Geron Corporation Stock Is Jumping Today
Shares of the clinical-stage biotech Geron Corporation (NASDAQ: GERN) rose by as much as 13.5% in early morning trading today, thanks to a Fast Track designation from the U.S. Food and Drug....
Pfizer Inc. Q3 Earnings: The Most Important Things to Know
Pfizer's (NYSE: PFE) overall story so far in 2017 has been a mediocre one. The big pharma company's stock is up year to date, but barely half as much as the S&P 500 index. Although Pfizer....
Exact Sciences' Earnings Hammer Short-Sellers (Again)
Americans have historically done poorly when it comes to sticking to recommended guidelines for colon cancer screening, but a new test launched by Exact Sciences (NASDAQ: EXAS) may be changing....
If Celgene Buys This Biotech, Investors Should Win Big-Time
Celgene (NASDAQ: CELG) has fallen on hard times of late -- or its stock has, at least. At the beginning of October, the biotech's share price was up 25% year to date. By the end of the month,....
Und täglich grüßt ein neues Allzeithoch!
Nach der EZB-Entscheidung letzte Woche haben die Börsen nochmals einen kräftigen Schub nach oben bekommen. DAX, MDAX, TECDAX, SDAX und die amerikanischen Indizes wie der S&P 500 und der Dow....
Why Adamas Pharmaceuticals Inc. Jumped Higher Today
Adamas Pharmaceuticals (NASDAQ: ADMS) closed up 21% on Monday, after Point72 Asset Management disclosed in an SEC document on Friday after the bell that it boosted its stake in the drugmaker.The....
Better Buy: Intuitive Surgical, Inc. vs. Johnson & Johnson
With multiple catalysts likely to fuel its growth, the healthcare sector is fertile ground from which investors can reap sizable profits -- if you know where to look.To help you in this regard,....
Global Blood Therapeutics Inc. Jumped as Much as 14% on This News
Shares of San Francisco-based Global Blood Therapeutics (NASDAQ: GBT), a small-cap developer of experimental therapies focused on treating blood-based disorders, rocketed higher by as much as 14%....
Celgene Corporation Has "Optionality and Opportunity"
Celgene (NASDAQ: CELG) got crushed after announcing third-quarter earnings, saying revenue would come in at the bottom of previous guidance, and lowering its 2020 guidance. All things considered,....
MEDICREA : RACHAT ACTIONS - CONTRAT DE LIQUIDITE - SEPTEMBRE 2017
PROGRAMME DE RACHAT DE TITRES
Dénomination sociale de l'émetteur :
MEDICREA
Numéro de visa du programme :
Nature des....
Why Advanced Accelerator Applications SA Acquired a Higher Price Today
Advanced Accelerator Applications (NASDAQ: AAAP) is up 10.5% at 11:42 a.m. EDT after announcing that it was being acquired by Novartis (NYSE: NVS) for approximately $3.9 billion.Advanced....
Why TransEnterix Stock Is Rebounding Today
TransEnterix (NYSEMKT: TRX), a small-cap robotic-surgery company, is on the rebound today with its shares up by 21.41% on heavy volume, as of 11:05 a.m. EDT.Prior to today's double-digit move,....
3 High-Yield International Stocks
Because of the generally more favorable corporate tax rates abroad, international stocks can, on occasion, offer enormous yields that are sustainable in the long term. The international investing....
2 Top Pharma Stocks on Sale This Week
Like most investors, I love a good bargain. So when the top pharma stocks Celgene Corporation (NASDAQ: CELG) and GlaxoSmithKline plc (NYSE: GSK) both crashed last week, it definitely caught my....
The 3 Best Diabetes Stocks to Buy in 2018
Diabetes is a chronic condition that occurs when the body loses its ability to properly metabolize sugar. Without treatment, people with diabetes end up with too much sugar flowing through their....
3 Reasons I've Been Aggressively Buying Intercept Pharmaceuticals
I admit it: I love trying to catch a falling knife. Sometimes you get sliced in the process, while at other times you leave vindicated by having gone against the grain. My belief is that small-cap....
How to Invest in Healthcare
Ten thousand Americans will turn 65 years old every day from now through 2029. As those Americans age, they will transform our country's healthcare system -- to the tune of a 5.8% annual increase....
ResMed's Sales and Profits Rise
ResMed (NYSE: RMD), a medical device marker focused on continuous positive airway pressure (CPAP) machines and accessories, reported its fiscal first-quarter results on Thursday, Oct. 26. The....
VISIOMED GROUP décroche la certification médicale européenne pour BewellCheck-up(R), la 1ère solution d'interprétation médicale et d'orientation diagnostique dotée d'Intelligence Artificielle
Paris, le 30 octobre 2017
VISIOMED GROUP (FR0011067669 – ALVMG), société spécialisée dans l'électronique médicale nouvelle génération, annonce que BewellCheck-up® vient de décrocher la....
3 Biotech Stocks That Turned $1,000 Into More Than $5,000 This Year
It's been a banner year for anyone who started 2017 holding shares of AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), XOMA Corporation (NASDAQ: XOMA), or Dynavax Technologies Corporation (NASDAQ:....
5 Things You Need to Know From Gilead Sciences' Q3 Update
You could probably fit the number of people surprised by Gilead Sciences' (NASDAQ: GILD) third-quarter results inside a phone booth -- if you could even find one. Hepatitis C virus (HCV) drug....
Ending Obamacare's Cost-Sharing Reductions Will Lead to This Ironic Result
With open enrollment for the Affordable Care Act (ACA) just days away, you're liable to notice that Obamacare (the more common name for the ACA) will look a lot different in the upcoming year.Most....
A Me-Too Push By Biopharma Is Crowding the Psoriasis Market
A wave of R&D is leading to next-generation psoriasis drugs that work better than ever. That's great news for patients desperate for new treatment options, but it's bad news for biopharma....